Episodes 106-120 of 265
Insights from global key opinion leaders on optimizing patient care in NSCLC
MinuteCE®Insights from global key opinion leaders on optimizing patient care in NSCLC
Guidelines-recommended first-line treatment with immunotherapy-based regimens in PD-L1- positive metastatic NSCLC
MinuteCE®Guidelines-recommended first-line treatment with immunotherapy-based regimens in PD-L1- positive metastatic NSCLC
Incorporation of guidelines-concordant care for advanced NSCLC with second-line targeted therapies
MinuteCE®Incorporation of guidelines-concordant care for advanced NSCLC with second-line targeted therapies
Clinical evidence driving guidelines for immunotherapy in the neoadjuvant and adjuvant settings of NSCLC
MinuteCE®Clinical evidence driving guidelines for immunotherapy in the neoadjuvant and adjuvant settings of NSCLC
Incorporation of guidelines-concordant immunotherapy in the perioperative setting of NSCLC
MinuteCE®Incorporation of guidelines-concordant immunotherapy in the perioperative setting of NSCLC
Application of guidelines-recommended broad molecular profiling to patients with NSCLC
MinuteCE®Application of guidelines-recommended broad molecular profiling to patients with NSCLC
Redefining Treatment at First Relapse in RRMM: Exploring BCMA-Targeted Therapies
CME/CERedefining Treatment at First Relapse in RRMM: Exploring BCMA-Targeted Therapies
Empowering Choices: Navigating Early-Stage HR+, HER2- Breast Cancer with CDK4/6 Inhibition
CME/CEEmpowering Choices: Navigating Early-Stage HR+, HER2- Breast Cancer with CDK4/6 Inhibition
Bringing Treatment Into Focus: Biomarker-Driven First-Line Therapy for Metastatic Gastric/GEJ Cancers
CME/CEBringing Treatment Into Focus: Biomarker-Driven First-Line Therapy for Metastatic Gastric/GEJ Cancers
Maximizing Adherence and Persistence via Patient Engagement
MinuteCE®Maximizing Adherence and Persistence via Patient Engagement
Interprofessional Coordination of Adverse Event Management
MinuteCE®Interprofessional Coordination of Adverse Event Management
Case: A Patient With High-Risk HR+/HER2- EBC Potentially Eligible for CDK4/6 and/or PARP Inhibitor
MinuteCE®Case: A Patient With High-Risk HR+/HER2- EBC Potentially Eligible for CDK4/6 and/or PARP Inhibitor
Endpoints in Adjuvant Breast Cancer Trials: Implications for Clinical Practice
MinuteCE®Endpoints in Adjuvant Breast Cancer Trials: Implications for Clinical Practice
